AREVA: Multicenter Randomized Comparison of Low-Dose Versus Standard-Dose Anticoagulation in Patients With Mechanical Prosthetic Heart Valves
- 1 November 1996
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Circulation
- Vol. 94 (9) , 2107-2112
- https://doi.org/10.1161/01.cir.94.9.2107
Abstract
Moderate anticoagulation may be proposed to reduce the risk of hemorrhage for certain patients with a mechanical prosthesis, but the consequences for risk of thromboembolism are debated. The purpose of the AREVA trial was to compare moderate oral anticoagulation (international normalized ratio [INR] of 2.0 to 3.0) with the usual regimen (INR of 3.0 to 4.5) after a single-valve replacement with a mechanical prosthesis, either Omnicarbon or St Jude. Patients included were between 18 and 75 years old, in sinus rhythm, and with a left atrial diameter < or = 50 mm on the time-motion echocardiogram. Patients were randomized for INR after surgery. From 1991 to 1994, 433 patients underwent valve replacement (aortic, 414; mitral, 19) with 353 St Jude and 80 Omnicarbon prostheses; 380 patients were randomized for INR: 188 for INR 2.0 to 3.0 and 192 for INR 3.0 to 4.5. Mean follow-up was 2.2 years (1 to 4 years). Analysis of 18001 INR samples showed that the mean of the median of INR was 2.74 +/- 0.35 in the 2.0 to 3.0 group and 3.21 +/- 0.33 in the 3.0 to 4.5 group (P < .0001). Thromboembolic events, as assessed from clinical data and CT brain scans, occurred in 10 patients in the 2.0 to 3.0 INR group and 9 patients in the 3.0 to 4.5 INR group (P = .78). Hemorrhagic events occurred in 34 patients in the 2.0 to 3.0 INR group and 56 patients in the 3.0 to 4.5 INR group (P < .01), with 13 and 19 major hemorrhagic events, respectively (P = .29). In selected patients with mechanical prostheses, moderate anticoagulation prevents thromboembolic events as effectively as conventional anticoagulation and reduces the incidence of hemorrhagic events.Keywords
This publication has 18 references indexed in Scilit:
- Antithrombotic Therapy in Patients With Mechanical and Biological Prosthetic Heart ValvesChest, 1995
- Optimal Oral Anticoagulant Therapy in Patients with Mechanical Heart ValvesNew England Journal of Medicine, 1995
- Anticoagulant-related bleeding: Clinical epidemiology, prediction, and preventionThe American Journal of Medicine, 1993
- A Comparison of Aspirin with Placebo in Patients Treated with Warfarin after Heart-Valve ReplacementNew England Journal of Medicine, 1993
- Low-Intensity Anticoagulation in Mechanical Cardiac Prosthetic ValvesChest, 1991
- Guidelines on oral anticoagulation: second edition. British Society for Haematology. British Committee for Standards in Haematology. Haemostasis and Thrombosis Task Force.Journal of Clinical Pathology, 1990
- Trial of Different Intensities of Anticoagulation in Patients with Prosthetic Heart ValvesNew England Journal of Medicine, 1990
- Hematological complications with the St. Jude valve and reduced-dose CoumadinThe Annals of Thoracic Surgery, 1989
- RANDOMISED COMPARISON OF TWO INTENSITIES OF ORAL ANTICOAGULANT THERAPY AFTER TISSUE HEART VALVE REPLACEMENTThe Lancet, 1988
- Silent cerebral infarction in chronic atrial fibrillation.Stroke, 1987